Biostem Technologies (Otc: Bsem)

Biostem Technologies (Otc: Bsem) company information, Employees & Contact Information

BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioRetain processing method. BioRetain has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies' quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks ("AATB"). These systems and procedures are established per current Good Tissue Practices ("cGTP") and current Good Manufacturing Processes ("cGMP"). Our portfolio of quality brands includes VENDAJE, VENDAJE AC, and VENDAJE OPTIC. Each BioStem Technologies placental allograft is processed at the Company's FDA registered and AATB accredited site in Pompano Beach, Florida.

Company Details

Employees
53
Founded
-
Address
2836 Center Port Circle, Pompano Beach,fl 33064,united States
Industry
Biotechnology
HQ
Pompano Beach, FL
Looking for a particular Biostem Technologies (Otc: Bsem) employee's phone or email?

Biostem Technologies (Otc: Bsem) Questions

News

BioStem Technologies Appoints KPMG as its Independent Registered Public Accountant - GlobeNewswire

BioStem Technologies Appoints KPMG as its Independent Registered Public Accountant GlobeNewswire

BioStem Technologies Announces Insider Share Purchase by Chairman and Chief Executive Officer - Yahoo Finance

BioStem Technologies Announces Insider Share Purchase by Chairman and Chief Executive Officer Yahoo Finance

Leading MedTech Firm BioStem Technologies Announces Double-Header Investor Conference Schedule in NYC - Stock Titan

Leading MedTech Firm BioStem Technologies Announces Double-Header Investor Conference Schedule in NYC Stock Titan

BioStem Technologies Appoints Brandon Poe as Chief Financial Officer - GlobeNewswire

BioStem Technologies Appoints Brandon Poe as Chief Financial Officer GlobeNewswire

$100,000 Insider Buy: BioStem Technologies CEO Shows Confidence with 15.5K Share Purchase at $6.28-$6.51 - Stock Titan

$100,000 Insider Buy: BioStem Technologies CEO Shows Confidence with 15.5K Share Purchase at $6.28-$6.51 Stock Titan

BioStem Technologies to Host Second Quarter 2025 Financial Results Conference Call on August 14, 2025 - GlobeNewswire

BioStem Technologies to Host Second Quarter 2025 Financial Results Conference Call on August 14, 2025 GlobeNewswire

BioStem Technologies Reports Preliminary Second Quarter 2025 Financial Results - Yahoo Finance

BioStem Technologies Reports Preliminary Second Quarter 2025 Financial Results Yahoo Finance

BioStem Technologies Provides Update on the Company’s Form 10 Submission and SEC Review Process - GlobeNewswire

BioStem Technologies Provides Update on the Company’s Form 10 Submission and SEC Review Process GlobeNewswire

Ernst & Young LLP (EY US) Announces Jason Matuszewski, CEO - GlobeNewswire

Ernst & Young LLP (EY US) Announces Jason Matuszewski, CEO GlobeNewswire

BioStem Technologies Set to File Amended Form 10 as Nasdaq Uplisting Plans Progress - Stock Titan

BioStem Technologies Set to File Amended Form 10 as Nasdaq Uplisting Plans Progress Stock Titan

BioStem Technologies Reports Preliminary First Quarter 2025 Operating and Financial Results - GlobeNewswire

BioStem Technologies Reports Preliminary First Quarter 2025 Operating and Financial Results GlobeNewswire

BioStem Technologies Provides Comments on CMS CY 2026 Proposed Medicare Reimbursement Rule Changes for Skin Substitutes - Yahoo Finance

BioStem Technologies Provides Comments on CMS CY 2026 Proposed Medicare Reimbursement Rule Changes for Skin Substitutes Yahoo Finance

BioStem Technologies Launches Clinical Trial to Demonstrate - GlobeNewswire

BioStem Technologies Launches Clinical Trial to Demonstrate GlobeNewswire

BioStem Technologies Signs Letter of Intent to Acquire - GlobeNewswire

BioStem Technologies Signs Letter of Intent to Acquire GlobeNewswire

BioStem Technologies Reports Breakthrough Results with AmnioWrap2® in Retrospective Wound Care Study - Yahoo Finance

BioStem Technologies Reports Breakthrough Results with AmnioWrap2® in Retrospective Wound Care Study Yahoo Finance

Ernst & Young (EY) US Announces Jason Matuszewski, CEO of - GlobeNewswire

Ernst & Young (EY) US Announces Jason Matuszewski, CEO of GlobeNewswire

BioStem Technologies, Inc. Files Form 10 with the - GlobeNewswire

BioStem Technologies, Inc. Files Form 10 with the GlobeNewswire

BioStem Technologies, Inc. Announces Launch of AEON™ - BioInformant

BioStem Technologies, Inc. Announces Launch of AEON™ BioInformant

Top Biostem Technologies (Otc: Bsem) Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant